Clinical Trial

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-09-09.
Trial Details
NCT Number NCT05535413
Lead Sponsor Hunan Cancer Hospital
Conditions Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine, UDT1
Enrollment 30 participants
Start Date 2023-01-01
Primary Completion 2024-10-31 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-25